摘要
Immunotherapy,as one of the major strategies for cancer treatment,has shown promising efficacy in cancer treatment by the clinical application of programmed cell death protein-1/programmed cell death-ligand 1(PD-1/PD-L1)antibodies which have demonstrated a significant prolongation in the survival time of melanoma,lung,and liver cancer patients.[1–3].Meanwhile,the clinical observation of partial responses in unirradiated lesions after radiotherapy,termed as abscopal effect,has gradually attracted a lot of attention and has inspired oncologists to combine stereotactic radiotherapy(SABR)with immunotherapy for improving clinical outcomes.It is the abscopal effect phenomenon that crucially determines the anti-tumor efficiency of SABR and immune checkpoint inhibitors combination strategy[4].However,due to the short application time and limited experience of the clinical utilization of SABR and anti-PD-1/PD-L1 combination therapy,there are plenty of theoretical and practical issues that need to be systematically discussed,including the mechanisms underlying an abscopal effect,the efficacy and toxicity of combination therapy,and the validity or reliability of corresponding clinical trials.Here,we reviewed previous landmark reports and summarized the research progress of SABR combined with anti-PD-1/PLD-1 therapy to improve the understanding on abscopal effect.
基金
This research was funded by key clinical projects of Peking University Third Hospital(Peking University talent introduction fund,BYSY2017030).
作者简介
Correspondence:Hongqing Zhuang,https://orcid.org/0000-0003-1374-4095,49 North Garden Rd.,Haidian District Beijing 100191 P.R.China.Email:hongqingzhuang@163.com。
